Benefits of Cetyl Myristoleate

Evidence-Based Benefits

• Knee OA symptom reduction — Hesslink et al. (2002, n=64) found cetylated fatty acids significantly improved knee range of motion and function vs. placebo, with 63.5% of the treatment group showing improvement
• Joint lubrication — CMO integrates into cell membranes and acts as a surfactant in synovial fluid, reducing friction between cartilage surfaces during joint movement
• Anti-inflammatory action — CMO modulates prostaglandin and leukotriene production, reducing inflammatory mediators that contribute to joint pain and cartilage degradation
• Immune modulation — the original discovery in Swiss mice showed CMO provided complete protection against adjuvant-induced arthritis, suggesting powerful immune-regulatory properties

What the Research Says

Cetyl myristoleate has a limited but promising evidence base. The key trial by Hesslink et al. (2002) was a double-blind, placebo-controlled study of 64 knee OA patients that showed significant improvement in range of motion and functional performance with cetylated fatty acids over 68 days. Kraemer et al. (2004) demonstrated improvements in knee range of motion and overall function in a controlled trial. The original discovery by Diehl and May (1994) in Swiss albino mice provided the mechanistic rationale — these mice produce CMO naturally and are the only known mammalian species completely resistant to experimentally induced arthritis. While the evidence is encouraging, larger multi-center trials are needed to confirm these findings.

Related Conditions